Clinical findings
T2D, nausea, diarrhea, hyperplasia, pain, weight loss
HYPERPLASIA
There was no difference in the need for target lesion revascularization, nor in the amount of intima hyperplasia detected by OCT, between groups. In contrast, subjects treated with exenatide had a greater weight loss and decreased abdominal circumference, and a corresponding better glycemic control, compared to the control group; supporting the role on weight reduction and glycemic control for incretin treatment in people with T2D. Drop-outs were more frequent in the exenatide group (4 participants) than in the control group (1 participant), which were related to the study drug in two cases, i.e. one subject suffered from diarrhea and nausea and the other subject of pain during the subcutaneous injection administration. To note, one of the patients that discontinued the treatment with exenatide did complete the follow-up period and was analyzed for strut coverage as an intention to treat analysis.